Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Efatutazone (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 18 Jan 2014 Primary endpoint 'Progression-free-survival-rate' has not been met.
- 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History